American National Bank & Trust Sells 4,125 Shares of Johnson & Johnson $JNJ

Key Points

• American National Bank & Trust reduced its Johnson & Johnson stake by 4.6% in the third quarter, selling 4,125 shares and retaining 86,500 shares valued at approximately $22.9 million. Institutional investors collectively own 69.55% of the company.
• Johnson & Johnson reported quarterly EPS of $2.90, beating estimates by $0.06, while revenue rose 6.6% year over year to $25.31 billion. The company also pays a quarterly dividend of $1.34, equivalent to a 2.1% annual yield.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $276.22. However, insiders sold $23.1 million of shares in the last quarter, while biosimilar competition, patent expirations, MedTech headwinds and talc litigation remain risks.

American National Bank & Trust lessened its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 86,500 shares of the company's stock after selling 4,125 shares during the quarter. Johnson & Johnson makes up 2.0% of American National Bank & Trust's investment portfolio, making the stock its 13th largest holding. American National Bank & Trust's holdings in Johnson & Johnson were worth $22,900,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Worth Asset Management LLC lifted its stake in Johnson & Johnson by 18.5% in the third quarter. Worth Asset Management LLC now owns 3,254 shares of the company's stock worth $861,000 after acquiring an additional 508 shares during the last quarter. Crumly & Associates Inc. grew its position in shares of Johnson & Johnson by 29.5% during the third quarter. Crumly & Associates Inc. now owns 2,767 shares of the company's stock worth $733,000 after acquiring an additional 630 shares during the last quarter. First Community Trust NA grew its position in Johnson & Johnson by 11.0% during the 3rd quarter. First Community Trust NA now owns 2,817 shares of the company's stock worth $746,000 after purchasing an additional 280 shares during the last quarter. Waller Financial Planning Group Inc. purchased a new stake in shares of Johnson & Johnson during the third quarter worth approximately $203,000. Finally, Mallini Complete Financial Planning LLC lifted its stake in shares of Johnson & Johnson by 5.6% in the 3rd quarter. Mallini Complete Financial Planning LLC now owns 974 shares of the company's stock worth $258,000 after acquiring an additional 52 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 87,569 shares of company stock worth $23,064,544 in the last quarter. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 2.1%

NYSE:JNJ traded up $5.41 during mid-day trading on Wednesday, reaching $260.19. The stock had a trading volume of 2,000,223 shares, compared to its average volume of 7,963,346. The stock's 50 day simple moving average is $265.86 and its two-hundred day simple moving average is $248.63. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The company has a market capitalization of $627.03 billion, a price-to-earnings ratio of 30.16, a price-to-earnings-growth ratio of 2.48 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period last year, the firm posted $2.77 EPS. The company's revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JNJ shares. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $287.00 to $290.00 and gave the stock an "outperform" rating in a research note on Tuesday. The Goldman Sachs Group reaffirmed a "buy" rating and set a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Bank of America restated a "neutral" rating and set a $278.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Finally, TD Cowen upped their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $276.22.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support: Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying roughly 10% upside from recent levels. RBC Capital also maintained its “Buy” rating. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: Oncology pipeline progress: J&J reported that its Tecvayli-Talvey combination reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma. The results could support broader or earlier use of the combination, although it remains an investigational treatment. 2026 Cancer Treatment Advances
• Positive Sentiment: ICOTYDE durability: Two-year Phase 3 data showed that J&J’s oral psoriasis treatment maintained skin clearance and consistent safety through Week 112, strengthening its potential as a targeted alternative for difficult-to-treat areas. ICOTYDE Long-Term Psoriasis Data
• Positive Sentiment: Dividend appeal: J&J has recorded 64 consecutive years of dividend increases, reinforcing its reputation as a defensive income stock and potentially attracting investors amid market volatility. Johnson & Johnson Dividend Royalty Status
• Neutral Sentiment: Upcoming earnings: Investors are assessing whether Innovative Medicines growth can offset a recent MedTech slowdown, while the company’s next quarterly report approaches. Vision, Orthopedics and Surgery could support a second-half recovery, but competitive pressure remains.
• Negative Sentiment: Longer-term risks: Analysts and commentators continue to flag biosimilar competition, a roughly $4 billion 2027 patent cliff, MedTech headwinds and unresolved talc litigation. These issues could constrain growth and valuation even with strong dividend reliability.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.